UPDATE 1-Ironwood, Forest bowel drug meets main goal, shares up

* Late-stage study in US shows improvement over placebo

* European study data positive

* Plans to file for US marketing approval in Q3 2011

* Ironwood shares up 13 pct, Forest up 4 pct

Nov 1 (BestGrowthStock) – Ironwood Pharmaceuticals Inc (IRWD.O: ) and
Forest Laboratories Inc (FRX.N: ) said their treatment for
irritable bowel syndrome met the main goals of a late-stage
study, sending the companies shares up.

The companies expect to apply for market approval in the
third quarter of 2011 for the treatment of irritable bowel
syndrome with constipation as well as chronic constipation.

The study showed a significant improvement on all main
goals, including treating abdominal pain and complete
spontaneous bowel movements, in patients treated with the drug,
Linaclotide, compared with placebos, the companies said.

In a separate statement, Ironwood and Spanish drugmaker
Almirall (ALM.MC: ) said the drug met co-primary goals of a
second late-stage trial in Europe. The companies expect to file
for marketing approval in the second half of 2011.

Ironwood shares, which have risen 9 percent since the
company reported positive results for the drug in a late-stage
European trial in September, were up 13 percent at $11.95 in
extended trade.

Forest Labs’ shares, which have risen 21 percent in the
last six months, were 4 percent at $34.55.
(Reporting by Shravya Jain in Bangalore)

UPDATE 1-Ironwood, Forest bowel drug meets main goal, shares up